Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS MUTATION
NRAS MUTATION - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1227
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/208
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Does Not Support
- Drug
- Trametinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22805292
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Trametinib | Sensitivity | false |